

14. (Amended) The antigen composition of Claim 13, wherein the *E. rhusiopathiae* culture is inactivated.

15. (Amended) The antigen composition of Claim 13, wherein the *E. rhusiopathiae* culture is inactivated with formalin or with beta propiolactone.

16. (Amended) The antigen composition of Claim 13, wherein the fluid fraction is concentrated 6 to 20X.

17. (Amended) A vaccine composition comprising:

- (1) an antigen composition; and,
- (2) an adjuvant composition,

wherein the antigen composition comprises an *E. rhusiopathiae* culture fluid fraction and a stabilizing agent, wherein the stabilizing agent is a metal hydroxide, a metal phosphate, an aluminum hydroxide gel, a calcium phosphate gel, a zinc hydroxide/calcium hydroxide gel or an alum.

18. (Amended) A vaccine composition according to Claim 17 wherein the adjuvant composition comprises from about 0.25% to about 12.5% v/v of a lecithin, from about 1% to about 23% v/v of an oil and from about 1.5% to about 8% v/v of an amphiphilic surfactant in said vaccine composition.

Kindly add the following claims:

24. The antigen composition of Claim 13, wherein said stabilizing agent is aluminum hydroxide.
25. The antigen composition of Claim 13, wherein said stabilizing agent, aluminum hydroxide, is added to the concentrated composition to a final concentration of 30% v/v.
26. The vaccine composition of Claim 17, wherein said stabilizing agent is aluminum hydroxide.
27. The vaccine composition of Claim 17, wherein said stabilizing agent, aluminum hydroxide, is added to the concentrated composition to a final concentration of 30% v/v.
28. The vaccine composition of Claim 17, wherein said adjuvant composition comprises about 2% v/v lecithin, about 18% v/v mineral oil, and about 5.6% v/v Tween 80 and about 2.4% v/v Span 80 with the remaining volume being a saline solution.
29. The vaccine composition of Claim 17, wherein said composition is stable at 2°C to 8°C for at least one year and provides immunity to weaned pigs for six months.

30. A vaccine composition comprising:

- (1) an antigen composition; and,
- (2) an adjuvant composition,

wherein the antigen composition comprises an *E. rhusiopathiae* culture fluid fraction and a stabilizing agent wherein the stabilizing agent is aluminum hydroxide gel; and, wherein the adjuvant composition comprises about 2% v/v lecithin, about 18% v/v mineral oil, and about 5.6% v/v Tween 80, and about 2.4% v/v Span 80 with the remaining volume being a saline solution.